Skip to main
PCVX
PCVX logo

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc. is positioned favorably within the market for next-generation pneumococcal vaccines, evidenced by its VAX-24 and VAX-31 candidates demonstrating superior immune response in adult trials compared to existing products like Prevnar 20. The company's strong clinical performance, especially in infant populations with robust seroresponse rates, suggests a significant potential for sustained market leadership and expansion. With an estimated global revenue opportunity of $7-10 billion, Vaxcyte represents a compelling mid- to long-term investment in the biotech sector.

Bears say

Vaxcyte Inc. faces significant downside risks primarily stemming from potential delays in research and development processes as well as uncertainties regarding the efficacy and safety of its vaccine candidates, which could lead to disappointing clinical trial outcomes. The company is also susceptible to lower-than-anticipated commercial uptake and the possibility that competitor programs may progress more rapidly, adversely affecting its market position. Additionally, broader concerns related to anti-vaccine sentiment contribute to a negative sentiment surrounding Vaxcyte's stock, as reflected in the substantial decline in share value since late 2024.

Vaxcyte (PCVX) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.